Agios Pharmaceuticals, Inc. (AGIO)
32.32
+1.35
(+4.36%)
USD |
NASDAQ |
Oct 15, 16:00
32.28
-0.04
(-0.11%)
After-Hours: 20:00
Agios Pharmaceuticals Cash from Operations (TTM) : -360.60M for June 30, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | -360.60M |
| March 31, 2026 | -380.41M |
| December 31, 2025 | -372.98M |
| September 30, 2025 | -409.93M |
| June 30, 2025 | -406.00M |
| March 31, 2025 | -401.46M |
| December 31, 2024 | -389.84M |
| September 30, 2024 | -329.16M |
| June 30, 2024 | -306.59M |
| March 31, 2024 | -300.75M |
| December 31, 2023 | -296.06M |
| September 30, 2023 | -289.74M |
| June 30, 2023 | -299.44M |
| March 31, 2023 | -306.93M |
| December 31, 2022 | -309.48M |
| September 30, 2022 | -327.41M |
| June 30, 2022 | -341.24M |
| March 31, 2022 | -384.31M |
| December 31, 2021 | -407.32M |
| September 30, 2021 | -372.62M |
| June 30, 2021 | -355.65M |
| March 31, 2021 | -306.15M |
| December 31, 2020 | -290.76M |
| September 30, 2020 | -334.97M |
| June 30, 2020 | -352.36M |
| Date | Value |
|---|---|
| March 31, 2020 | -372.71M |
| December 31, 2019 | -370.62M |
| September 30, 2019 | -351.20M |
| June 30, 2019 | -329.45M |
| March 31, 2019 | -308.69M |
| December 31, 2018 | -304.42M |
| September 30, 2018 | -304.69M |
| June 30, 2018 | -318.56M |
| March 31, 2018 | -310.16M |
| December 31, 2017 | -285.23M |
| September 30, 2017 | -262.00M |
| June 30, 2017 | -233.32M |
| March 31, 2017 | -16.50M |
| December 31, 2016 | 38.56M |
| September 30, 2016 | 59.26M |
| June 30, 2016 | 83.47M |
| March 31, 2016 | -70.37M |
| December 31, 2015 | -76.95M |
| September 30, 2015 | -54.20M |
| June 30, 2015 | -52.85M |
| March 31, 2015 | -57.90M |
| December 31, 2014 | -59.35M |
| September 30, 2014 | -65.20M |
| June 30, 2014 | -56.71M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 160.32M |
| Biogen, Inc. | 2.879B |
| Insmed, Inc. | -778.92M |
| Alnylam Pharmaceuticals, Inc. | 885.89M |
| Regeneron Pharmaceuticals, Inc. | 4.681B |